Amwell Announces Reverse Stock Split
Amwell (NYSE: AMWL) announced a 1-for-20 reverse stock split of its Class A, B, and C common stock, effective on July 10, 2024, at 5:00 p.m. EDT. Trading on a split-adjusted basis will commence on July 11, 2024, under the same symbol, 'AMWL'.
The primary objective is to comply with the NYSE's $1.00 minimum average closing price requirement. This action will reduce the number of issued and outstanding shares across all classes by a factor of 20, without affecting the company's market capitalization.
Shareholders approved the reverse split at Amwell's annual meeting on June 18, 2024, choosing a split ratio between 1-for-10 and 1-for-20, with the final decision made by the Board on June 27, 2024. No fractional shares will be issued; instead, cash payments will be made for fractional entitlements.
The new CUSIP number for Class A shares will be 03044L 204 post-split. All outstanding options, warrants, and equity incentive plans will be adjusted accordingly. The par value remains unchanged at $0.01 per share.
- The reverse stock split will help Amwell comply with the NYSE's $1.00 minimum average closing price requirement.
- The action may broaden Amwell's investor base and optimize cash flow efficiency.
- The reverse stock split significantly reduces the number of issued and outstanding shares, which could impact shareholder perceptions.
A reverse stock split consolidates the number of existing shares into fewer, proportionally more valuable shares. While it doesn't change the company's market capitalization, it often signals underlying financial or market challenges. In this case, Amwell is addressing its compliance with the NYSE's $1.00 minimum average closing price requirement. This move is important for maintaining their listing status, which is vital for liquidity and investor confidence.
For the short-term, the reverse split could lead to a temporary uptick in the stock price simply due to the reduced number of shares. However, it is essential for investors to understand that such a split doesn't inherently increase the intrinsic value of the company. The company’s fundamentals remain the same.
In the long-term, the success of this strategy depends on Amwell's ability to execute its plans for efficiency, optimized cash flow and profitable growth. Investors should closely monitor the company’s financial performance in subsequent quarters to ensure these goals are being met. The consolidation could make the stock more attractive to institutional investors who might be restricted from investing in lower-priced stocks.
Amwell’s decision to proceed with a 1-for-20 reverse stock split is a clear attempt to maintain compliance with the NYSE listing requirements, but it also reflects broader market conditions. The telehealth sector experienced a significant boom during the COVID-19 pandemic, but as the world normalizes, companies like Amwell face new challenges to sustain growth and investor interest.
This move to consolidate shares may help Amwell broaden its investor base and stabilize its stock price by reducing volatility that can occur with penny stocks. However, the perception of reverse stock splits can be mixed. It may be viewed negatively by some investors, suggesting that the company is struggling to maintain its stock price. Conversely, it could be seen as a positive step towards achieving a more stable and higher stock price.
Investors should seek additional details on how Amwell plans to leverage its current market position to drive growth, particularly in a competitive and evolving sector. Close attention should be paid to strategic initiatives, partnerships and technological advancements that could affect the company’s future performance.
Boston, June 28, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a small-cap growth healthcare company and a leading provider of healthcare software as a service, today announced that its Board of Directors (the “Board”) has approved a 1-for-20 reverse stock split (“Reverse Split”) of its Class A common stock, Class B common stock and Class C common stock (collectively, the “Common Stock”), that is expected to become effective on July 10, 2024 at 5:00 p.m. EDT. The shares of the Company’s Class A common stock are expected to begin trading on the New York Stock Exchange (“NYSE”) on a split-adjusted basis at the market open on July 11, 2024. No change will be made to the trading symbol for the Company’s shares of Class A common stock, “AMWL”, in connection with the Reverse Split.
The Company expects that the Reverse Split will allow the Company to regain compliance with the
“While the reverse stock split is primarily driven by technical compliance with the NYSE minimum stock price requirement, we also hope to broaden the base of potential investors in Amwell as we strive for greater efficiencies, optimized cash flow and profitable growth, while remaining committed to enabling our clients to achieve their goals. The split also has no direct impact on our market capitalization,” said Robert Shepardson, Amwell CFO.
At the Company’s annual meeting of stockholders held on June 18, 2024, the Company’s stockholders approved the proposal to authorize the Board, in its discretion, to effect the Reverse Split at a ratio to be determined by the Board, ranging from 1-for-10 to 1-for-20. On June 27, 2024, the Board approved the Reverse Split.
The Reverse Split will reduce the number of issued and outstanding shares of Class A common stock from approximately 266,174,000 to approximately 13,308,700, the number of issued and outstanding shares of Class B common stock from approximately 27,390,397 to approximately 1,369,519 and the number of issued and outstanding shares of Class C common stock from approximately 5,555,555 to approximately 277,777. All outstanding options, warrants, and other securities entitling their holders to purchase or otherwise receive shares of Common Stock will be adjusted as a result of the Reverse Split. The number of shares available to be awarded under the Company’s equity incentive plans will also be appropriately adjusted. Following the Reverse Split, the par value of the Common Stock will remain unchanged at
Additional information regarding the Reverse Split is available in the Company’s definitive proxy statement originally filed with the U.S. Securities and Exchange Commission (SEC) on April 26, 2024.
About Amwell
Amwell provides a leading hybrid care enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. The company offers a single comprehensive platform to support all digital health needs, from urgent to acute and post-acute care, chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/.
©2024 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.
Forward-Looking Statements
This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations, financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our beliefs and assumptions only as of the date of this release. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: our ability to regain and maintain compliance with NYSE listing standards; our ability effect any reverse stock split; our ability to successfully transition our clients to Converge without significant attrition; our ability to renew and upsell our client base; the election by the Defense Health Agency to deploy our solution across their entire enterprise; the continuation of the DHA relationship beyond July of 2025 with comparable financial terms; weak growth and increased volatility in the telehealth market; our ability to adapt to rapid technological changes; increased competition from existing and potential new participants in the healthcare industry; changes in healthcare laws, regulations or trends and our ability to operate in the heavily regulated healthcare industry; our ability to comply with federal and state privacy regulations; the significant liability that could result from a cybersecurity breach; and other factors described under ‘Risk Factors’ in our most recent form 10-K filed with the SEC. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission. These filings, when available, are available on the investor relations section of our website at investors.amwell.com and on the SEC’s website at www.sec.gov.
FAQ
What is Amwell's reverse stock split ratio for AMWL?
When will Amwell's reverse stock split become effective?
Why is Amwell implementing a reverse stock split for AMWL?
When will AMWL shares start trading on a split-adjusted basis?
Will Amwell's market capitalization change due to the reverse stock split?
What is the new CUSIP number for AMWL Class A common stock after the reverse split?
How will fractional shares be handled in Amwell's reverse stock split?
